Q1 EPS Forecast for Neurocrine Biosciences Cut by Analyst

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Wedbush reduced their Q1 2025 EPS estimates for shares of Neurocrine Biosciences in a note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico now expects that the company will earn $1.10 per share for the quarter, down from their prior estimate of $1.33. Wedbush currently has a “Outperform” rating and a $147.00 target price on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q3 2025 earnings at $1.15 EPS, Q1 2026 earnings at $1.31 EPS, Q2 2026 earnings at $1.60 EPS and Q3 2026 earnings at $1.84 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%.

Other research analysts have also recently issued reports about the stock. Canaccord Genuity Group lowered their target price on shares of Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating on the stock in a report on Friday, February 7th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 20th. JPMorgan Chase & Co. raised their price objective on Neurocrine Biosciences from $183.00 to $184.00 and gave the company an “overweight” rating in a report on Wednesday, March 26th. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $185.00 price target on shares of Neurocrine Biosciences in a research report on Friday, February 21st. Three investment analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average price target of $161.86.

Neurocrine Biosciences Trading Up 1.3 %

Neurocrine Biosciences stock opened at $101.38 on Thursday. The company has a market capitalization of $10.03 billion, a price-to-earnings ratio of 30.81, a PEG ratio of 0.77 and a beta of 0.33. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $157.98. The stock’s 50 day moving average is $108.66 and its 200-day moving average is $122.48.

Hedge Funds Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Neurocrine Biosciences by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company’s stock valued at $1,381,331,000 after acquiring an additional 122,681 shares during the period. Dodge & Cox lifted its holdings in shares of Neurocrine Biosciences by 134.2% during the 4th quarter. Dodge & Cox now owns 3,016,425 shares of the company’s stock worth $411,742,000 after acquiring an additional 1,728,605 shares during the last quarter. AQR Capital Management LLC lifted its stake in Neurocrine Biosciences by 2.9% during the fourth quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company’s stock worth $258,926,000 after purchasing an additional 53,610 shares during the last quarter. Geode Capital Management LLC boosted its stake in Neurocrine Biosciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company’s stock worth $255,523,000 after buying an additional 15,830 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Neurocrine Biosciences by 102.9% in the 4th quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company’s stock valued at $198,939,000 after purchasing an additional 739,199 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 623 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $149.29, for a total transaction of $93,007.67. Following the completion of the sale, the insider now owns 3,442 shares in the company, valued at approximately $513,856.18. This represents a 15.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kevin Charles Gorman sold 2,707 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.92, for a total transaction of $413,954.44. Following the completion of the sale, the director now owns 517,030 shares of the company’s stock, valued at approximately $79,064,227.60. This represents a 0.52 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 167,906 shares of company stock worth $24,671,530. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences announced that its Board of Directors has authorized a stock repurchase plan on Friday, February 21st that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the company to purchase up to 4.2% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.